India's healthcare and pharmaceutical industry has strongly contested the United States Trade Representative's USTR 'Excess Capacity' Claim that the country maintains “excess capacity” in pharmaceutical manufacturing. Industry representatives asserted that India's production capabilities have evolved to meet growing global demand for affordable, high-quality medicines, rather

